Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women
Authors:
Open Access
- 7 June 2017
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 14 (2) , 1561-1567
Abstract
Previous studies have reported that basic fibroblast growth factor (bFGF) is associated with tumor genesis, growth and prognosis. The present study was conducted to detect the levels of bFGF expression in women with non-small cell lung cancer (NSCLC), colon cancer, breast cancer and melanoma, and analyze its association with the clinicopathological characteristics of malignant tumors. The tumor tissues were obtained from 508 female patients with malignant tumors between March 2008 and May 2015 (103 NSCLC, 147 colon cancer, 206 breast cancer and 52 melanoma). Histological examination was performed on paraffin-embedded tissues. The immunohistochemical peroxidase-conjugated streptavidin method was used to detect bFGF protein expression in the tissues. The level of bFGF protein expression was significantly increased in patients with NSCLC with poor differentiation and lymph node metastasis compared with patients with moderately/well differentiated NSCLC without lymph node metastasis. Increased levels of bFGF protein expression were observed in patients with colon cancer with lymph node metastasis compared with patients without lymph node metastasis, and in patients with breast cancer with tumor-node-metastasis stage III–IV and lymph node metastasis compared with patients in stage I–II and without lymph node metastasis. The rate of positive bFGF staining in patients with melanoma with lymph node metastasis was significantly higher compared with patients without lymph node metastasis. These results suggested that bFGF may be associated with the process of malignant tumor genesis and growth, and the expression of bFGF protein may be a potential and effective biomarker for diagnosing malignant tumor metastasis in females. The present study may also provide theoretical bases for the clinical application of bFGF monoclonal antibody in molecular targeted therapies in tumors.Keywords
This publication has 24 references indexed in Scilit:
- Frondoside A Suppressive Effects on Lung Cancer Survival, Tumor Growth, Angiogenesis, Invasion, and MetastasisPLOS ONE, 2013
- Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer CellsMolecular Pharmacology, 2009
- Expression of Angiogenesis-Related Genes Regulates Different Steps in the Process of Tumor Growth and Metastasis in Human Urothelial Cell Carcinoma of the Urinary BladderPathobiology, 2008
- Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell LinesMolecular Cancer Research, 2006
- YM-359445, an Orally Bioavailable Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor, Has Highly Potent Antitumor Activity against Established TumorsClinical Cancer Research, 2006
- Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesisCytokine & Growth Factor Reviews, 2005
- Importance of Vascular Phenotype by Basic Fibroblast Growth Factor, and Influence of the Angiogenic Factors Basic Fibroblast Growth Factor/Fibroblast Growth Factor Receptor-1 and Ephrin-A1/EphA2 on Melanoma ProgressionThe American Journal of Pathology, 2002
- Autocrine production of basic fibroblast growth factor translated from novel synthesized mRNA mediates thrombin‐induced mitogenesis in smooth muscle cellsCell Biochemistry and Function, 2001
- Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formationJournal of Clinical Investigation, 2000
- Fibroblast Growth FactorClinical Orthopaedics and Related Research, 1990